Cormorant Global Healthcare Master Fund, LP, 10% Owner at EyePoint Pharmaceuticals, Inc. (EYPT), bought 1,163,530 shares at $18.90 ($21.0M) on 2024-04-18, disclosed to the SEC on 2024-04-22.
Open-market purchase of $21.0M EYPT by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.62 | 395,244 | $7.0M | 33.2% |
| 2 | $17.62 | 395,244 | $7.0M | 33.2% |
| 3 | $18.90 | 186,521 | $3.5M | 16.8% |
| 4 | $18.90 | 186,521 | $3.5M | 16.8% |
| Total | $18.03 avg | 1,163,530 | $21.0M | 100% |
| Filing → |
| DRUG | BUY | 2024-10-17 | $6.4M | — | Filing → |
| CRBP | BUY | 2024-09-24 | $14.0M | — | Filing → |
| IMRX | SELL | 2024-03-18 | $4.6M | — | Filing → |